Alnylam Pharmaceuticals
ALNY
#591
Rank
NZ$58.40 B
Marketcap
$452.78
Share price
-0.29%
Change (1 day)
57.92%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Operating Margin for Alnylam Pharmaceuticals (ALNY)

Operating Margin as of November 2024 (TTM): -23.71%

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current Operating Margin is -23.71%. At the end of 2023 the company had an Operating Margin of -23.71%.

Operating Margin history for Alnylam Pharmaceuticals from 2003 to 2024

Operating Margin at the end of each year

Year Operating Margin Change
2023-23.71%-78.17%
2022-108.63%7.63%
2021-100.93%-41.86%
2020-173.60%-56.91%
2019-402.85%-60.33%
2018-1,015.48%86%
2017-545.95%-37.22%
2016-869.63%23.21%
2015-705.83%-10.92%
2014-792.32%306.56%
2013-194.88%11.54%
2012-174.73%150.82%
2011-69.66%62.06%
2010-42.98%-8.07%
2009-46.76%76.12%
2008-26.55%-83.16%
2007-157.61%7.45%
2006-146.68%-80.71%
2005-760.53%0.84%
2004-754.18%-93.51%
2003-11,618.18%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
-85.77% 261.75%๐Ÿ‡บ๐Ÿ‡ธ USA
35.88%-251.33%๐Ÿ‡บ๐Ÿ‡ธ USA
4.13%-117.42%๐Ÿ‡บ๐Ÿ‡ธ USA
-34.14% 43.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-118.00% 397.68%๐Ÿ‡บ๐Ÿ‡ธ USA
25.49%-207.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
15.40%-164.95%๐Ÿ‡ซ๐Ÿ‡ท France
-3.93%-83.42%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.